Drug Interactions With Risk of QT-prolongation in a General Hospital
- Registration Number
- NCT02043912
- Lead Sponsor
- KU Leuven
- Brief Summary
In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation. Additional clinical risk factors for developing QT-prolongation and safety measurements will be documented.
- Detailed Description
Study design: epidemiological point prevalence study
Target population: Patients with haloperidol treatment
The following aspects will be investigated:
* The medication profiles will be checked for drug interactions with risk of QT-prolongation.
* Clinical risk factors for developing QT-prolongation (gender, age, (history of) cardiovascular disease, comorbidity,...) and lab results will be collected.
* Safety measurements (e.g. ECG) will be documented.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 222
- treatment with haloperidol (started in the hospital)
- age < 18 years
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description patients treated with haloperidol Haloperidol -
- Primary Outcome Measures
Name Time Method QTc-interval (corrected for heart rate) maximum one year before inclusion / one week after inclusion
- Secondary Outcome Measures
Name Time Method number of drug interactions (with risk of QT-prolongation) one week before/after inclusion
Trial Locations
- Locations (1)
Universitair Ziekenhuis Leuven
🇧🇪Leuven, Belgium